Review: Rosiglitazone increase risk for MI but does not differ from other drugs for CV death in type 2 diabetes
- Spiriva HandiHaler update. // Monthly Prescribing Reference;Feb2010, Vol. 26 Issue 2, pA18
The article reports on the announcement of the U.S. Food and Drug Administration (FDA) which states that data from the review of Spiriva HandiHaler, a tiotropium dry powder for inhalation, is not capable of supporting an increased risk of stroke, heart attack or death.
- Stealth Salt. Kuzemchak, Sally // Prevention;Mar2007, Vol. 59 Issue 3, p85
This article reports on the dangerously high levels of sodium present in popular foods. Foods like salad dressing, ham sandwiches, and muffins reportedly raise blood pressure and impede lung function. The American Medical Association has reportedly asked the United States Food and Drug...
- RED YEAST RICE: CHOLESTEROL CURE? // Prevention;Apr2007, Vol. 59 Issue 4, p34
The article reports on red yeast rice as a remedy for high cholesterol. Research studies claim that the rice can lower the bad cholesterol, low density lipoproteins (LDL), and raise the good cholesterol, high density lipoproteins (HDL). The rice allegedly contains a substance that is similar to...
- New Use Approved for Vioxx. // FDA Consumer;Jul/Aug2002, Vol. 36 Issue 4, p3
Reports that the U.S. Food & Drug Administration has approved the use of Vioxx, or rofecoxib, for rheumatoid arthritis. Previous approval of Vioxx for osteoarthritis and pain; Approval of a label text and precautions which are based on the results of a one-year study; Finding that Vioxx was...
- Non-aspirin NSAIDs cause MI, stroke: stronger FDA warning. // Reactions Weekly;Jul2015, Vol. 1561 Issue 1, p2
The article reports that the U.S. Food and Drug Administration (FDA) strengthens the warning about the increase risk of stroke and myocardial infarction (MI) associated with nonsteroidal anti-inflammatory drugs (NSAIDs) by requiring update for prescription NSAID labels.
- FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards Marwick, Charles // JAMA: Journal of the American Medical Association;2/14/96, Vol. 275 Issue 6, p423
Discusses the reasons why the Food and Drug Administration (FDA) advisory committee cautioned physicians whose patients receive short-acting nifedipine as treatment for hypertension because of the risk of myocardial infarction, especially at higher doses, to these patients.
- Use of Placebos Poses Ethical Dilemma. Nayak, Devdutt; Chodha, Vicky // Psychiatric Annals;Feb2014, Vol. 44 Issue 2, p89
The term "placebo" lives in infamy in the history of medicine and medical research because of its association with fraud, fakery, coercion, and abuse and has promulgated progressively stricter regulations and guidelines. Opposition to using placebo control in clinical trials is based on the...
- Responding to an FDA Warning ï¿½ Geographic Variation in the Use of Rosiglitazone. Shah, Nilay D.; Montori, Victor M.; Krumholz, Harlan M.; Tu, Karen; Alexander, G. Caleb; Jackevicius, Cynthia A. // New England Journal of Medicine;11/25/2010, Vol. 363 Issue 22, p2081
The article discusses the results of the retrospective analysis that was conducted using the National Prescription Audit and the Xponent database to determine the impact of the boxed warning issued by the U.S. Food and Drug Administration (FDA) on the risk of myocardial infarction on the use of...
- Study links diabetes drug to heart deaths. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);5/26/2007, Vol. 334 Issue 7603, p1073
This article reports on the findings of a meta-analysis of 42 trials on the use of the drug Avandia which was published in the "New England Journal of Medicine." The analysis found that the diabetes drug rosiglitazone has shown an increased risk of myocardial infarction and an increase in...